Microcap Ledger Precision Biosciences Inc $DTIL
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Durham, NC
- Fiscal year end
- May 21
- Shares outstanding
- 27,601,554 [10-Q 2026-08-06]
What the company doesAI summary of filing
Precision BioSciences is a clinical-stage gene editing company that develops in vivo gene editing therapies using its proprietary ARCUS platform. The company is advancing two lead clinical programs: PBGENE-HBV for chronic hepatitis B treatment and PBGENE-DMD for Duchenne muscular dystrophy, as well as partnered programs including ECUR-506 for ornithine transcarbamylase deficiency being developed with iECURE. The company generates revenue through upfront payments, milestone payments, and royalties from license agreements with partners such as Caribou Biosciences, TG Therapeutics, Imugene, and iECURE, and through exclusive licenses of foundational technology from Duke University and Cellectis. As a clinical-stage company, Precision BioSciences is pre-revenue from product sales and relies on milestone and licensing payments and capital raises to fund its operations. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $10.84M | −$51.09M | −$25.38M | $86.08M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $34.26M | −$45.72M | −$65.84M | $110.82M | [10-K 2026-03-12] |
| FY ended Dec 2024 | $68.70M | $7.17M | −$58.45M | $85.90M | [10-K 2026-03-12] |
- Quarterly cash burn
- −$12.69M
- Cash runway Estimate
- ~20.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 7,671,059 | [10-Q 2024-11-04] |
| 2025-03-20 | 10,481,931 | [10-K 2025-03-26] |
| 2025-05-08 | 11,088,234 | [10-Q 2025-05-15] |
| 2025-07-31 | 11,786,991 | [10-Q 2025-08-07] |
| 2025-10-29 | 13,256,751 | [10-Q 2025-11-03] |
| 2026-03-05 | 24,726,695 | [10-K 2026-03-12] |
| 2026-04-30 | 25,802,247 | [10-Q 2026-05-05] |
| 2026-08-03 | 27,601,554 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-12-30; declared effective 2026-01-07 [S-3 2025-12-30]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-28 | Frankel Stanley | buy | 1,000 | $6.00 | [4 2026-09-30] |
| 2026-09-25 | Brown Melinda | buy | 1,135 | $6.27 | [4 2026-09-29] |
| 2026-09-25 | Germano Geno J | buy | 2,609 | $6.28 | [4 2026-09-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-24 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-24 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-29 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-27 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-07-20 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-01 | 8-K | Regulation FD disclosure; Other events |
| 2026-06-16 | 8-K | Material agreement entered; New financial obligation |
| 2026-05-27 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-26 | 8-K | Director or officer change; Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-05-05 | 10-Q | Quarterly report |
Alerts for $DTIL
Email me when Precision Biosciences Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.